經尿道膀胱腫瘤汽化電切術聯合表柔比星治療非肌層浸潤性膀胱癌的臨床效果

　　[摘要]目的 探究經尿道膀胱腫瘤汽化電切術聯合表柔比星治療非肌層浸潤性膀胱癌的臨床效果。方法 選取2014年3月～2016年3月我院收治的40例非肌層浸潤性膀胱癌患者隨機分配的原則分為觀察組（n=20）和對照組（n=20）。兩組均給予經尿道膀胱腫瘤汽化電切術進行治療，對照組加用羥喜樹堿或米托蒽醌進行膀胱灌注，觀察組加用表柔比星進行膀胱灌注，對比兩組患者的導尿管留置時間﹑手術時間﹑不良反應及復發(fā)情況。結果 兩組患者導尿管留置時間﹑手術時間比較，差異無統(tǒng)計學意義（P>0.05）；兩組患者不良反應發(fā)生率比較，差異無統(tǒng)計學意義（χ2=0.28，P=0.60）；兩組患者復發(fā)率比較，差異無統(tǒng)計學意義（χ2=0.20，P=0.66）。結論 經尿道膀胱腫瘤汽化電切術聯合表柔比星治療非肌層浸潤性膀胱癌的效果確切，復發(fā)率低，值得推廣。
　　[關鍵詞]經尿道膀胱腫瘤汽化電切術；表柔比星；非肌層浸潤性膀胱癌
　　[中圖分類號] R737.1 [文獻標識碼] A [文章編號] 1674-4721（2018）2（b）-0089-03
　　Clinical effect of transurethral resection of bladder tumor combined with epirubicin in the treatment of non muscle invasive bladder cancer
　　HUANG Zhi-cheng PENG Dong CHEN Zhi-lin WAN Pei ZHU Yu-guang CHEN Nan-hui
　　The Four Department of Urology， Meizhou People"s Hospital in Guangdong Province， Meizhou 514000，China
　　[Abstract]Objective To explore the clinical effect of transurethral bladder tumor vaporizing electrotomy combined with epi in the treatment of non-muscular infiltrating bladder cancer.Methods 40 patients of non-muscle invasive bladder cancer treated in our hospital from March 2014 to March 2016 were divided into observation group （n=20） and control group （n=20）.Two groups were given transurethral electrovaporization of bladder tumor treatment，the control group with hydroxycamptothecin or mitoxantrone for bladder perfusion，observation group with epirubicin for bladder perfusion.The catheter indwelling time，operation time，adverse reactions and recurrence were compared between the two groups.Results There was no significant difference in indwelling time and operation time between the two groups （P>0.05）.There was no significant difference in the incidence of adverse reactions between the two groups （χ2=0.28，P=0.60）.There was no significant difference in recurrence rate between the two groups （χ2=0.20，P=0.66）.Conclusion Transurethral electrovaporization resection of bladder tumor combined with epirubicin in the treatment of non-muscle invasive bladder cancer is effective，the recurrence rate is low， worthy of promotion.
　　[Key words]Transurethral resection of bladder tumor；Epirubicin；Non muscle invasive bladder cancer
　　膀胱癌是發(fā)生于泌尿系統(tǒng)的常見惡性腫瘤之一，多來源于上皮組織，長期接觸橡膠﹑塑料﹑染料等致癌物質，膀胱的長期炎癥反應和異物的刺激及吸煙等均會誘發(fā)膀胱癌的發(fā)生[1-2]。膀胱癌在病理組織類型上主要表現為上皮性腫瘤，可占其總數的90%以上，只有少部分患者可表現為肉瘤或者橫紋肌肉瘤等非上皮性腫瘤[3]。非肌層浸潤性膀胱癌可包括TNM分期中的Tis﹑Ta﹑T1，針對Ta﹑T1期腫瘤，經尿道膀胱腫瘤電切術是臨床上主要考慮的治療方法。經尿道膀胱腫瘤汽化電切術對于表淺膀胱腫瘤可以有較好的治療效果，但是基于膀胱癌的復發(fā)率較高，在手術的基礎上常常會應用一些藥物進行膀胱灌注化療。表柔比星、羥喜樹堿及米托蒽醌等是膀胱癌治療中常用的行膀胱灌注的化療藥物[4]，因此，本研究對兩種常用藥物的效果進行了探索，希望可以為膀胱癌的治療提供一種可靠的治療方案，現報道如下。

相關熱詞搜索：膀胱癌 汽化 尿道 膀胱 腫瘤